Evidence map›Paper›PMID 34675883›Full record

ArticleFrontiers in endocrinology2021

Pharmacological Inhibition of Inositol-Requiring Enzyme 1α RNase Activity Protects Pancreatic Beta Cell and Improves Diabetic Condition in Insulin Mutation-Induced Diabetes.

Oana Herlea-Pana, Venkateswararao Eeda, Ram Babu Undi, Hui-Ying Lim, Weidong Wang

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Oana Herlea-PanaDepartment of Medicine, Division of Endocrinology, Harold Hamm Diabetes Center, Oklahoma City, OK, United States.
Venkateswararao EedaDepartment of Medicine, Division of Endocrinology, Harold Hamm Diabetes Center, Oklahoma City, OK, United States.
Ram Babu UndiDepartment of Physiology, Harold Hamm Diabetes Center, The University of Oklahoma Health Science Center, Oklahoma City, OK, United States.
Hui-Ying LimDepartment of Physiology, Harold Hamm Diabetes Center, The University of Oklahoma Health Science Center, Oklahoma City, OK, United States.
Weidong WangDepartment of Medicine, Division of Endocrinology, Harold Hamm Diabetes Center, Oklahoma City, OK, United States.
Iowa Diabetes and Endocrinology Research Center · USUniversity of Oklahoma Health Sciences Center · US

Funding

Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Wade Williams · 2018 to 2026
$27.1M
Understanding connective tissue development and disease with PDGFR-driven..... P20GM103636 · NIGMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI THOMPSON, LINDA F · 2013 to 2023
$26.9M
Pilot Project ProgramP30GM122744 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI LE, YUN ZHENG · 2017 to 2021
$5.5M
Preclinical Validation of PPARg Acetylation Inhibitors for Diabetes Prevention and TreatmentR01DK128848 · NIDDK · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI WANG, WEIDONG · 2021 to 2025
$2.4M
Developing proinsulin misfolding inhibitors for beta cell protection and diabetes treatmentR01DK130174 · NIDDK · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Weidong Wang · 2022 to 2026
$1.9M
Cytoprotection and the mechanism of action of a natural product Khellin against ER stressR01DK116017 · NIDDK · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI WANG, WEIDONG · 2018 to 2021
$1.6M
Preclinical Development of Khellin Analogs for Anti-Diabetic TherapyR56DK108887 · NIDDK · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI WANG, WEIDONG · 2016 to 2017
$444k
NCI NIH HHS P30 CA225520NIDDK NIH HHS R01 DK116017NIDDK NIH HHS R01 DK128848NIDDK NIH HHS R01 DK130174NIDDK NIH HHS R56 DK108887NIGMS NIH HHS P20 GM103636NIGMS NIH HHS P30 GM122744
6 · The paper itself

Abstract

β-cell ER stress plays an important role in β-cell dysfunction and death during the pathogenesis of diabetes. Proinsulin misfolding is regarded as one of the primary initiating factors of ER stress and unfolded protein response (UPR) activation in β-cells. Here, we found that the ER stress sensor inositol-requiring enzyme 1α (IRE1α) was activated in the Akita mice, a mouse model of mutant insulin gene-induced diabetes of youth (MIDY), a monogenic diabetes. Normalization of IRE1α RNase hyperactivity by pharmacological inhibitors significantly ameliorated the hyperglycemic conditions and increased serum insulin levels in Akita mice. These benefits were accompanied by a concomitant protection of functional β-cell mass, as shown by the suppression of β-cell apoptosis, increase in mature insulin production and reduction of proinsulin level. At the molecular level, we observed that the expression of genes associated with β-cell identity and function was significantly up-regulated and ER stress and its associated inflammation and oxidative stress were suppressed in islets from Akita mice treated with IRE1α RNase inhibitors. This study provides the evidence of the

Indexed as

AnimalsApoptosisDiabetes Mellitus, ExperimentalEndoplasmic Reticulum StressEndoribonucleasesEnzyme InhibitorsGene Expression RegulationGlucose Tolerance TestInsulinInsulin-Secreting CellsIslets of LangerhansMiceMice, Inbred C57BLMutationProtective AgentsProtein Serine-Threonine KinasesEndoribonucleasesEnzyme InhibitorsErn1 protein, mouseInsulinProtective AgentsProtein Serine-Threonine KinasesBeta cell failurebeta cell protectionER stressIre1alphaIre1alpha inhibitionmonogenic diabetesproinsulin misfoldingunfolded protein response

Identifiers

PMID34675883
PMCPMC8524045
OpenAlexW3204045656

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.